<DOC>
	<DOCNO>NCT03103724</DOCNO>
	<brief_summary>Open label , single arm , phase II multicentre study design determine clinical benefit , measure 3-months disease control rate ( DCR ) provide enzalutamide metastatic Castration Resistant Prostate Cancer patient least one visceral site involvement .</brief_summary>
	<brief_title>A Phase II Study Evaluating Efficacy Enzalutamide Role ARv7 Metastatic Castration Resistant Prostate Cancer ( mCRPC ) Patients With Visceral Disease .</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Age &gt; 18 2 . ECOG PS 012 3 . Biopsy ( primary tumour metastasis ) confirm diagnosis prostate adenocarcinoma 4 . Documented measurable metastatic visceral disease ( accord RECIST 1.1 criterion ) consider metastasis lung liver extraregional lymphnodes 5 . Written inform consent 6 . Platelets &gt; = 100 x109/L ; haemoglobin &gt; = 9 g/dl ; neutrophil &gt; 1.5 x 109/L 7 . Bilirubin &lt; = 2 mg/dl , AST ALT &lt; = 2.5 time UNL &lt; = 5 time UNL pt liver metastasis ; serum albumin &gt; = LNL 8 . Patients childbearing age use contraceptive method 9 . Life expectancy &gt; 3 month 10 . Able swallow study drug comply study requirement ; 11 . Willing able give inform consent . 12 . Ongoing androgen deprivation therapy GnRH analogue orchiectomy ( i.e. , surgical medical castration ) ; 13 . Patients may receive previous therapy include chemotherapy ( docetaxel ) last cycle must receive 3 week start experimental treatment . Hormonal treatment contain bicalutamide must interrupt 2 week start study therapy 14 . Previous radiotherapy ( prostate and/or bone ) accept must interrupt 3 week start experimental treatment . 15 . Serum testosterone level &lt; 1.7 nmol/L ( 50 ng/dL ) Screening visit 16 . Progressive disease PSA image set medical surgical castration . Disease progression study entry define one follow three criterion ( accord PCWG2 ) : PSA progression define minimum three rise PSA level interval ≥ 1 week determination . The PSA value Screening visit ≥ 2 g/L ( 2 ng/ml ) ; third PSA value less second PSA , fourth PSA must repeat value high second must consider disease Soft tissue/visceral disease progression define RECIST 1.1 ; Bone disease progression define two new lesion bone scan . 1 . Severe , concurrent disease , infection , comorbidity , judgment investigator , would make patient inappropriate enrollment ; 2 . Metastases brain active epidural disease ; 3 . History another malignancy within previous 5 year curatively treat nonmelanomatous skin cancer ; 4 . History seizure , include febrile seizure , loss consciousness , transient ischemia attack within 12 month enrollment ( Day 1 visit ) , condition may predispose seizure ( e.g. , prior stroke , head trauma loss consciousness require hospitalization ) ; 5 . Clinically significant cardiovascular disease include : Myocardial infarction within 6 month ; Uncontrolled angina within 3 month ; Congestive heart failure New York Heart Association ( NYHA ) class 3 4 , patient history congestive heart failure NYHA class 3 4 past , unless screen echocardiogram multigated acquisition scan ( MUGA ) perform within 3 month result leave ventricular ejection fraction ≥ 45 % ; 6 . Diagnosed suspected congenital long QT syndrome ; 7 . History clinically significant ventricular arrhythmia ( e.g. , ventricular tachycardia , ventricular fibrillation , torsades de pointes ) ; 8 . Gastrointestinal disorder affect absorption ( e.g. , gastrectomy , active peptic ulcer within last 3 month ) ; 9 . Major surgery within 4 week prior enrollment ( Day 1 visit ) ; 10 . Prior treatment abiraterone acetate ; 11 . Participation clinical trial experimental antiandrogen agent ( eg . ARN509 , ODM201 , VT464 , except placebo arm ) ; 12 . Treatment ( concomitant previous 2 week ) antiandrogens ( eg . Bicalutamide , nilutamide , flutamide ) 5a reductase inhibitor ( eg . finasteride , dutasteride ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>